Why is Eli Lilly stock surging today?

AlzeCure Pharma received a $10M upfront payment from Eli Lilly for the Alzheimer’s project Alzstatin, including drug candidate ACD680. The deal includes potential milestone payments and royalties, with a total value exceeding $1B. Lilly gains global rights to Alzstatin. AlzeCure's CEO noted the payment strengthens their financial position and they will continue work in Alzheimer’s and pain projects.

Eli Lilly (LLY) received UK approval for its oral GLP-1 drug, Foundayo, for weight management and type 2 diabetes, marking its first European regulatory win. This follows Novo Nordisk's (NVO) earlier approval of its oral Wegovy in the UK and EU. Foundayo's once-daily, no-restriction design may offer a competitive advantage. Both companies are expanding in the growing weight loss drug market.

Moderna and Merck's experimental cancer vaccine showed promising Phase 3 results, preventing melanoma recurrence in certain patients. This drove significant stock price increases for both companies and other biopharma stocks, including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and BioNTech. Moderna's shares surged 138%, while Merck's rose 12.4%. The broader biopharma sector has been on an upswing, with investors rotating away from tech stocks. President Trump's nomination of a new FDA commiss

Eli Lilly shares closed 1.9% below their all-time high after a 3.6% rise. Q2 revenue surged 48% to $22.97B, with volume up 60% but prices down 13%. Mounjaro and Zepbound contributed 64% of sales. Lilly raised its 2026 revenue outlook to $85B-$87B. Competition and pricing pressures remain key concerns.

Eli Lilly (LLY) reported strong Q2 2026 results, with Mounjaro and Zepbound generating $9.94B and $4.93B respectively, up 91% and 46% YoY. Novo Nordisk (NVO) saw flat sales for Ozempic and Wegovy. Lilly's Foundayo, though early, shows growth potential. Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are developing competing oral GLP-1 drugs. LLY stock is up 14% YTD, trading at a higher P/E than its industry.

Eli Lilly's stock rose 5.8% after Q2 results beat expectations, with revenue up 48% YoY to $22.97B and adjusted EPS up 33% to $8.38. GLP-1 drugs Mounjaro and Zepbound drove growth, contributing 65% of revenue. Lilly raised its sales forecast and highlighted strong pipeline prospects, including new obesity treatments and next-gen GLP-1 therapies.